Table 5.

Most Common Treatment-Emergent Adverse Events by Baseline Dyskinesia Status During the Double-Blind Maintenance Period (Randomized Population)

Preferred Term	No Dyskinesia		Non-Troublesome Dyskinesia Only		Troublesome Dyskinesia
	CD-LD ER	CD-LD IR	CD-LD ER	CD-LD IR	CD-LD ER	CD-LD IR
	(N = 91)	(N = 92)	(N = 66)	(N = 65)	(N = 44)	(N = 35)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Subjects with at least one event	37 (40.7)	35 (38.0)	28 (42.4)	28 (43.1)	22 (50.0)	13 (37.1)
Fall	1 (1.1)	0 (0.0)	1 (1.5)	3 (4.6)	4 (9.1)	1 (2.9)
Insomnia	2 (2.2)	1 (1.1)	4 (6.1)	1 (1.5)	1 (2.3)	0 (0.0)
Nausea	5 (5.5)	2 (2.2)	1 (1.5)	0 (0.0)	0 (0.0)	1 (2.9)
Oedema peripheral	2 (2.2)	1 (1.1)	2 (3.0)	3 (4.6)	0 (0.0)	0 (0.0)
Sleep disorder	2 (2.2)	2 (2.2)	2 (3.0)	1 (1.5)	0 (0.0)	1 (2.9)
Upper respiratory tract infection	2 (2.2)	3 (3.3)	0 (0.0)	1 (1.5)	2 (4.5)	0 (0.0)
Urinary tract infection	1 (1.1)	3 (3.3)	1 (1.5)	1 (1.5)	2 (4.5)	0 (0.0)
Back pain	1 (1.1)	1 (1.1)	1 (1.5)	3 (4.6)	1 (2.3)	0 (0.0)
Dizziness	2 (2.2)	2 (2.2)	3 (4.5)	0 (0.0)	0 (0.0)	0 (0.0)
Dyskinesia	1 (1.1)	0 (0.0)	2 (3.0)	1 (1.5)	2 (4.5)	1 (2.9)

Note: Adverse events were coded according to the Medical Dictionary for Regulatory Activities version 12.1. If subject had multiple events with the same preferred term, the subject was counted only once. CD-LD ER, carbidopa-levodopa extended release; CD-LD IR, carbidopa-levodopa immediate release.